Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy

UCB

Status and phase

Completed

Phase 3

Conditions

Epilepsy

Treatments

Drug: Brivaracetam (BRV)

Study type

Interventional

Funder types

Industry

Identifiers

NCT01364597

2011-000374-60 (EudraCT Number)

N01266

Details and patient eligibility

About

This study will evaluate the safety and tolerability of brivaracetam in pediatric subjects with epilepsy.

Full description

This is a Phase 3, open-label, single-arm, multicenter, long-term study to evaluate the safety and efficacy of brivaracetam (BRV) in children with epilepsy.

This study was initially designed for pediatric subjects who had completed a previous BRV study.

With protocol amendment 4, enrollment for "directly enrolled" subjects was modified from 'up to' an additional 100 subjects to "at least" 100 subjects, keeping the planned total enrollment of approximately 600 subjects to allow flexibility in the number of patients reaching 1 year of exposure.

With protocol amendment 5, entry criteria for subjects coming for other pediatric core studies in development were included. Additional clarity was provided for subjects enrolled in N01266 that temporary roll over to one of those studies and resume participation in N01266.

With protocol amendment 6, central EEG reading and entry visit EEG were removed. Some clarifications on study assessments (questionnaires, EEGs) was provided and inclusion criteria were aligned from an earlier local amendment.

With protocol amendment 7, the pregnancy section was updated to clarify that Pregnancy Report and Outcome Form has to be completed in all pregnancies.

With protocol amendment 8, re-categorization of study variables in compliance with reporting registries was performed. Modifications due to COVID19 pandemic were implemented and clarification provided that participants may transition to another BRV study.

The primary objective is to evaluate the long-term safety and tolerability of BRV. The secondary objective is to assess the efficacy of BRV during long-term exposure.

Enrollment

257 patients

Sex

All

Ages

28 days to 17 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

All Subjects:

Informed Consent form (ICF) is signed and dated by the parent(s) or legal representative(s)
Subject/legal representative is considered reliable and capable of adhering to the protocol
For female subjects:
Subject is not of childbearing potential

OR if women of childbearing potential, and sexually active only if:

Adequate Contraceptive method
Negative pregnancy test
Understands the consequences and potential risks of inadequately protected sexual activity, understands and properly uses contraceptive methods, and is willing to inform the Investigator of any contraception changes

Long Term Follow-up Subjects:

- Male or female subjects having participated in a core study with a confirmed diagnosis of epilepsy and for whom a reasonable benefit from long-term administration of BRV is expected

Directly Enrolled Subjects:

Subject is a male or female ≥4 years to <17 years of age
Subject has a clinical diagnosis of partial-onset seizures (POS) according to the International League Against Epilepsy (ILAE) classification
Subject has an EEG compatible with the clinical diagnosis of POS
Subject has been observed to have uncontrolled POS after an adequate course of treatment (in the opinion of the Investigator) with at least 1 antiepileptic drug (AED; concurrently or sequentially)
Subject had at least 1 seizure (POS) during the 3 weeks before the Screening Visit (ScrV)
Subject is taking at least 1 AED. All AEDs need to be at a stable dose for at least 7 days before the ScrV. Vagal nerve stimulator stable for at least 2 weeks before the ScrV is allowed and will be counted as a concomitant AED. Benzodiazepines taken more than once a week (for any indication) will be considered as a concomitant AED

Exclusion criteria

All Subjects:

Subject is a pregnant or nursing female
Subject has severe medical, neurological, or psychiatric disorders or laboratory values, which may have an impact on the safety of the subject.
Subject has planned participation in any clinical study of another investigational drug or device.
Subject has >1.5x upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or >1.0xULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert's syndrome). If subject has elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to identify possible undiagnosed Gilbert's syndrome (ie, direct bilirubin <35%). N01349 subjects with a total bilirubin > ULN may be considered for the study if benign unconjugated hyperbilirubinemia is suspected in the context of prolonged neonatal jaundice, after discussion with the medical monitor. For randomized subjects with a baseline result >ULN for ALT, AST, ALP, or total bilirubin, a baseline diagnosis and/or the cause of any clinically meaningful elevation must be understood and recorded in the eCRF. If subject has >ULN ALT, AST, or ALP that does not meet the exclusion limit at the baseline referenced in Table 5-1 for LTFU subjects and at the Screening Visit for directly enrolled subjects, repeat the tests, if possible, prior to dosing to ensure there is no further ongoing clinically relevant increase. In case of a clinically relevant increase, inclusion of the subject must be discussed with the Medical Monitor. Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated once for confirmation. This includes re-screening.
Subject has chronic liver disease.

Long Term Follow-up Subjects:

Subject had hypersensitivity to BRV or excipients or comparative drugs as stated in this protocol during the course of the core study.
Subject had poor compliance with the visit schedule or medication intake in the core study.
Subject ≥6 years of age has a lifetime history of suicide attempt (including actual attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ("Yes") to Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at the EV. If a subject has active suicidal ideation without a specific plan as indicated by a positive response ("Yes") to Question 4 of Columbia-Suicide Severity Rating Scale (C SSRS) at the EV, the subject should be referred immediately to a Mental Healthcare Professional and may be excluded from the study based upon the Investigator's judgment of benefit/risk of continuing the subject in the study/on study medication.

Directly Enrolled Subjects:

Subject has previously received BRV.
Subject had concomitant use of LEV at the ScrV. In addition, the use of LEV is prohibited for at least 4 weeks prior to the ScrV.
Subject has epilepsy secondary to a progressive cerebral disease or tumor, or any other progressively neurodegenerative disease. Stable arteriovenous malformations, meningiomas or other benign tumors may be acceptable according to Investigator's opinion.
Subject has a history of primary generalized epilepsy.
Subject has a history of status epilepticus in the month immediately prior to the ScrV or during the Up Titration Period.
Subject has a history or presence of pseudoseizures.
Subject is suffering only from febrile seizures.
Subject is on felbamate with less than 18 months continuous exposure. Subject who has taken felbamate for a combined duration of treatment and wash out of <18 months before the ScrV.
Subjects treated with vigabatrin who have visual field defects.
Subject has an allergy to pyrrolidone derivatives or investigational product excipients or a history of multiple drug allergies.
Subject has any clinically significant acute or chronic illness as determined during the physical examination or from other information available to the Investigator (eg, bone marrow depression, chronic hepatic disease, severe renal impairment, psychiatric disorder).
Subject has an underlying disease or is receiving a treatment that may interfere with the absorption, distribution, metabolism, and elimination of the study drug.
Subject has any medical condition that might interfere with his/her study participation (eg, serious infection or scheduled elective surgery).
Subject has a terminal illness.
Subject has any clinically significant deviations from reference range values for laboratory parameters as determined by the Investigator.
Subject has a clinically relevant ECG abnormality according to the Investigator.
Subject had major surgery within 6 months prior to the ScrV.
Subject received any investigational drug or device within the 30 days prior to the ScrV.